Bynfezia Pen is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 4 US drug patents filed from 2020 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 03, 2040. Details of Bynfezia Pen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11246991 | Electrolysis-resistant coupling assembly for valves |
Nov, 2040
(15 years from now) | Active |
| US11534553 | Method of injecting octreotide acetate into the body |
Nov, 2040
(15 years from now) | Active |
| US11052196 | Method of injecting octreotide acetate into the body |
Nov, 2040
(15 years from now) | Active |
| US10342850 | Octreotide injection |
May, 2038
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bynfezia Pen's patents.
Latest Legal Activities on Bynfezia Pen's Patents
Given below is the list of recent legal activities going on the following patents of Bynfezia Pen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Jan, 2023 | US10342850 |
| Patent Issue Date Used in PTA Calculation Critical | 09 Jul, 2019 | US10342850 |
| Recordation of Patent Grant Mailed Critical | 09 Jul, 2019 | US10342850 |
| Email Notification Critical | 20 Jun, 2019 | US10342850 |
| Issue Notification Mailed Critical | 19 Jun, 2019 | US10342850 |
| Dispatch to FDC | 10 Jun, 2019 | US10342850 |
| Printer Rush- No mailing | 07 Jun, 2019 | US10342850 |
| Email Notification Critical | 07 Jun, 2019 | US10342850 |
| Mail Miscellaneous Communication to Applicant | 07 Jun, 2019 | US10342850 |
| Miscellaneous Communication to Applicant - No Action Count | 30 May, 2019 | US10342850 |
US patents provide insights into the exclusivity only within the United States, but Bynfezia Pen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Bynfezia Pen's family patents as well as insights into ongoing legal events on those patents.
Bynfezia Pen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Bynfezia Pen's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 03, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bynfezia Pen Generic API suppliers:
Octreotide Acetate is the generic name for the brand Bynfezia Pen. 11 different companies have already filed for the generic of Bynfezia Pen, with Sun Pharm Inds having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Bynfezia Pen's generic
Alternative Brands for Bynfezia Pen
There are several other brand drugs using the same active ingredient (Octreotide Acetate) as Bynfezia Pen. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Chiesi |
| ||
| Novartis |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Octreotide Acetate, Bynfezia Pen's active ingredient. Check the complete list of approved generic manufacturers for Bynfezia Pen
About Bynfezia Pen
Bynfezia Pen is a drug owned by Sun Pharmaceutical Industries Ltd. Bynfezia Pen uses Octreotide Acetate as an active ingredient. Bynfezia Pen was launched by Sun Pharm in 2024.
Approval Date:
Bynfezia Pen was approved by FDA for market use on 27 September, 2024.
Active Ingredient:
Bynfezia Pen uses Octreotide Acetate as the active ingredient. Check out other Drugs and Companies using Octreotide Acetate ingredient
Dosage:
Bynfezia Pen is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 7MG/2.8ML (2.5MG/ML) | SOLUTION | Prescription | SUBCUTANEOUS |